BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer

Authors

Rebecca Byler Dann, University of Pittsburgh
Julie A. DeLoia, George Washington University
Kirsten M. Timms, Myriad Genetics, Salt Lake City, UT
Kristin K. Zorn, University of Pittsburgh
Jennifer Potter, University of Pittsburgh
Darl D. Flake II, Myriad Genetics, Salt Lake City, UT
Jerry S. Lanchbury, Myriad Genetics, Salt Lake City, UT
Thomas C. Krivak, University of Pittsburgh

Document Type

Journal Article

Publication Date

6-2012

Journal

Gynecologic Oncology

Volume

Volume 125, Issue 3

Inclusive Pages

677-682

Keywords

Genes; BRCA1; Genes; BRCA2; Germ-Line Mutation; Neoplasms; Glandular and Epithelial--drug therapy; Neoplasms; Glandular and Epithelial--genetics; Organoplatinum Compounds--therapeutic use; Ovarian Neoplasms--drug therapy; Ovarian Neoplasms--genetics

APA Citation

Dann, R. B., Deloia, J. A., Timms, K. M., Zorn, K. K., Potter, J., Flake II, D. D., Lanchbury, J.S., Krivak, T. C. (2012). BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecologic Oncology, 125(3), 677-682.

Peer Reviewed

1